Alemtuzumab (Campath-1H) in kidney transplantation

American Journal of Transplantation

Volumn 8, Issue 1, 2008, Pages 15-20

  Ciancio, G ^a   Burke III, G W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Acute rejection; Alemtuzumab; Induction therapy; Mycophenolate mofetil; Renal allograft; Sirolimus; Tacrolimus

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; IMMUNOGLOBULIN G1; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; FOLLOW UP; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; LUNG TOXICITY; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 37549043953     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.02053.x     Document Type: Short Survey

References (41)

1. Pirsch JD, Miller J, Deierhoi MH, Vicenti F, Filo R. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997 63 : 977 983.
2. Ciancio G, Burke GW, Suzart K et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002 73 : 1100 1106.
3. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000 342 : 605 612.
4. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004 4 : 1289 1295.
5. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326 2333.
6. Gloor JM, Sethi S, Stegall MD et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007 7 : 2124 2132.
7. Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DRJ. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007 7 : 2114 2123.
8. ®)/sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004 77 : 244 251.
9. ®)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at one year. Transplantation 2004 77 : 252 258.
10. Ciancio G, Miller J, Garcia-Morales RO et al. Six year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001 71 : 827 835.
11. Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999 68 : 480 484.
12. Waldmann H, Hale G. Alemtuzumab: From concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005 360 : 1707 1711.
13. Calne R, Moffatt SD, Friend PJ et al. Alemtuzumab 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999 68 : 613 616.
14. Flynn JM, Byrd JC. Alemtuzumab monoclonal antibody therapy. Curr Opin Oncol 2000 12 : 574 581.
15. Watson CJE, Bradley JA, Friend PJ et al. Alemtuzumab (Alemtuzumab 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005 5 : 1347 1353.
16. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Alemtuzumab). Transplantation 2003 76 : 120 129.
17. Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with Alemtuzumab. Am J Transplant 2006 6 : 1084 1085.
18. Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999 354 : 1691 1695.
19. Kirk AD, Mannon RB, Kleiner DE et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxypergualin. Transplantation 2005 80 : 1051 1059.
20. Thomas JM, Contreras JL, Jiang XL. Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999 68 : 1660.
21. Amemiya H. Deoxyspergualin: Immunosuppressive properties. Norwalk, CY : Appleton and Lange, 1989.
22. Knechtle SJ, Pirsch JD, Fechner J Jr. et al. Alemtuzumab induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003 3 : 722 730.
23. Barth RN, Janus CA, Lillesand CA et al. Outcomes at 3 years of prospective pilot study of Alemtuzumab and sirolimus immunosuppression for renal transplantation. Transplant Int 2006 19 : 885 892.
24. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005 5 : 3009 3014.
25. Gruessner RWG, Kandaswamy R, Humar A, Gruessner AC, Sutherland DER. Calcineurin inhibitor and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005 79 : 1184 1189.
26. Knechtle SJ, Fernandez LA, Pirsch JD et al. Alemtuzumab in renal transplantation: The University of Wisconsin experience. Surgery 2004 136 : 754 760.
27. Shapiro R, Basu A, Tzan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Alemtuzumab. J Am Coll Surg 2005 200 : 505 515.
28. Tan HP, Kaczorowski DJ, Basu M et al. Living donor renal transplantation using Alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006 6 : 2409 2417.
29. Ciancio G, Burke GW, Gaynor JJ et al. The use of Alemtuzumab as induction therapy in renal transplantation: Preliminary results. Transplantation 2004 78 : 426 433.
30. Ciancio G, Sageshima J, Gaynor JJ et al. The use of Alemtuzumab as induction therapy to achieve steroid avoidance in African-American and Hispanic first renal transplant recipients [abstract]. Am J Transplant 2006 1324 : 513.
31. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Alemtuzumab 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007 83 : 1509 1512.
32. Vathsala A, Ona ET, Tan SY et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005 80 : 765 774.
33. Ciancio G, Burke G, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005 80 : 457 465.
34. Kaufman DB, Leventhal JR, Axelrod D et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction - long-term results. Am J Transplant 2005 5 : 2539 2548.
35. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant 2006 6 : 331 339.
36. Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Alemtuzumab and renal transplant rejection. Clin Transplant 2004 8 : 759 - 761.
37. Peleg AY, Husain S, Kwak EJ et al. Opportunistic infections in 547 organ transplant recipients receiving Alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007 44 : 204 212.
38. Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005 5 : 465 474.
39. Hill P, Galiardini E, Ruggenenti P, Remuzzi G. Severe early acute humoral rejection resulting in allograft loss in renal transplant recipient with Alemtuzumab induction therapy. Nephrol Dial Transplant 2005 : 1741 1744.
40. Noris M, Casiraghi F, Todeschini M et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007 18 : 1007 1018.
41. Kang SM, Tang Q, Bluestone JA. CD4+CD25+ regulatory T cells in transplantation: Progress, challenges and prospects. Am J Transplant 2007 7 : 1457 1463.